Profil
Mr. Paul A. Howard is Founding Partner at Mediphase Venture Partners.
He is on the Board of Directors at Serenex, Inc.
Mr. Howard was a Senior Vice President at Hambrecht & Quist Capital Management in Boston from 1992-1999, where he was responsible for managing the fund's biotechnology investments.
From 1983-1990, he was a Senior Technical Sales Executive for the Miles Biotechnology Division of Bayer A.G.
Mr. Howard earned an AB from Bowdoin College in 1981, an MS from the University of Massachusetts, Amherst in 1983, and an S.M.
from the Sloan School of Management at M.I.T.
in 1992.
He serves on the Board of Directors of Supplemental Health Care and Serenex.
Aktive Positionen von Paul A. Howard
| Unternehmen | Position | Beginn |
|---|---|---|
Limulus Management Co. LLC
Limulus Management Co. LLC Investment ManagersFinance Limulus Management Co LLC invests in healthcare/life science companies located in the US. The firm focuses on companies with intellectual property positions and growth potential. It targets companies operating in the fields of biopharmaceutical technology and life sciences information. It provides financing for early stage capital requirements with an investment size ranging from $4 to $8 million. | Gründer | 03.01.2011 |
Wellpartner LLC
Wellpartner LLC Medical DistributorsDistribution Services Provides pharmacy distribution solutions and contract pharmacy administration services | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Paul A. Howard
| Unternehmen | Position | Ende |
|---|---|---|
Tekla Capital Management LLC
Tekla Capital Management LLC Investment ManagersFinance Tekla primarily focuses on healthcare investing. Their funds invest in public and private growth equities in the healthcare and life sciences industries. | Portfolio Manager-Aktien | 31.12.1998 |
Bayer AG /Plasma Products Business/
Bayer AG /Plasma Products Business/ Pharmaceuticals: MajorHealth Technology Provides plasma products | Corporate Officer/Principal | 31.12.1989 |
| TETRAPHASE PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | - |
Serenex, Inc.
Serenex, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops drugs | Direktor/Vorstandsmitglied | - |
Ausbildung von Paul A. Howard
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Serenex, Inc.
Serenex, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops drugs | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
Tekla Capital Management LLC
Tekla Capital Management LLC Investment ManagersFinance Tekla primarily focuses on healthcare investing. Their funds invest in public and private growth equities in the healthcare and life sciences industries. | Finance |
Wellpartner LLC
Wellpartner LLC Medical DistributorsDistribution Services Provides pharmacy distribution solutions and contract pharmacy administration services | Distribution Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Bowdoin College
Bowdoin College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bayer AG /Plasma Products Business/
Bayer AG /Plasma Products Business/ Pharmaceuticals: MajorHealth Technology Provides plasma products | Health Technology |
University of Massachusetts
University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Limulus Management Co. LLC
Limulus Management Co. LLC Investment ManagersFinance Limulus Management Co LLC invests in healthcare/life science companies located in the US. The firm focuses on companies with intellectual property positions and growth potential. It targets companies operating in the fields of biopharmaceutical technology and life sciences information. It provides financing for early stage capital requirements with an investment size ranging from $4 to $8 million. | Finance |
















